Market Cap (In USD)
73.05 Million
Revenue (In USD)
-
Net Income (In USD)
-75.52 Million
Avg. Volume
459.89 Thousand
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 1.25-32.415
- PE
- -
- EPS
- -
- Beta Value
- 0.999
- ISIN
- US0080641071
- CUSIP
- 008064107
- CIK
- 1798749
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Timothy P. Noyes M.B.A.
- Employee Count
- -
- Website
- https://aerovatetx.com
- Ipo Date
- 2021-06-30
- Details
- Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
More Stocks
-
338100NH Prime REIT Co., Ltd.
338100
-
4099
-
ONEXOnex Corporation
ONEX
-
0KDH
-
INDOAMINIndo Amines Limited
INDOAMIN
-
SRECRSreechem Resins Limited
SRECR
-
ADM
-
0756